• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Acumen Pharmaceuticals Inc.

    4/23/25 4:23:58 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABOS alert in real time by email
    DEFA14A 1 defa14a2025.htm DEFA14A DEFA14A 2025

    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    Filed by the Registrant x
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    oPreliminary Proxy Statement
    oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    oDefinitive Proxy Statement
    xDefinitive Additional Materials
    oSoliciting Material Pursuant to § 240.14a-12
    Acumen Pharmaceuticals, Inc.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    xNo fee required.
    oFee paid previously with preliminary materials
    oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



     


     

    Get the next $ABOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABOS

    DatePrice TargetRatingAnalyst
    6/17/2025$4.00Buy
    Citigroup
    7/26/2024$7.00Buy
    Citigroup
    12/12/2023$8.00Buy
    Deutsche Bank
    7/20/2023$9.00 → $14.00Buy
    BofA Securities
    5/18/2023$13.00Overweight
    Cantor Fitzgerald
    7/15/2022$15.00Buy
    BTIG Research
    6/30/2022$15.00Buy
    H.C. Wainwright
    1/21/2022$16.00 → $14.00Neutral → Buy
    B of A Securities
    More analyst ratings

    $ABOS
    SEC Filings

    See more
    • Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)

      6/5/25 4:37:03 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.

      10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)

      5/13/25 4:36:39 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)

      5/13/25 7:32:31 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care